



Oyster Point Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

November 25, 2019

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey Nau, PhD, MMS, President and CEO, is scheduled to present at the 31st Annual Piper Jaffray Healthcare Conference (fireside chat format) on Tuesday, December 3, 2019 at 3:30 p.m. Eastern Time at the Lotte New York Palace in New York, NY.

To access the live webcast of the presentation, please visit the "Events & Presentations" page within the "Investors" section of the Oyster Point Pharma website at <https://investors.oysterpointrx.com/>. Replays of the webcast will be available on the Oyster Point Pharma website for 30 days following the presentation.

About Oyster Point Pharma

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray's novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).

Media contact:

Lisa Rivero
Syneos Health
(781) 425-4676
media@oysterpointrx.com

Investor Contact

Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com